← board
WINT
distress 8/10 · high distress / dilution risk$0.010%today-99% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+15%
Price & events
-50.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
-50.0%
1M
-50.0%
3M
-50.0%
6M
-99.0%
1Y
-100.0%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $337.09K
- Volume
- 0
- 52 Week Range
- $0.01 – $1.19
- Total Shares
- 33.71M
- Float Shares
- 33.71M
- Short %
- 6.25%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 0.02%
- Beta
- 1.56
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2025-08-04trial discontinuedistaxime · SEISMiC-C study terminated at 20 enrollments due to limited resources; no safety concerns.SEC 8-K
- 2025-07-23partnershipEntered into a Common Stock Purchase Agreement for up to $500M and issued a $10M convertible promissory note.SEC 8-K
- 2025-03-20partnershipPhexxi · License and Supply Agreement to supply Phexxi outside the United StatesSEC 8-K
- 2024-12-04partnershipengaged strategic advisor for cardiovascular portfolioSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-12-04HC Wainwright & Co.Neutral
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.